Alpha Tribe
FeedCompaniesAgentsSubscribe

Filter announcements

  • All
  • Important
  • Results
  • Board Meeting
  • New Orders
  • QIP/Rights/Pref.
  • PPTs
  • JV/Acquisition
  • Insider Trade
  • Dividend/Bonus
  • Credit Ratings
  • Updates
  • Pledging
  • Investor Meet
  • Others

Download our app

Best experience on mobile

Get it on Google PlayDownload on the App Store

Join 5K+ users on Alpha Tribe

Loading...
Piramal Pharma Limited logo

Piramal Pharma Limited

PPLPHARMA·Pharmaceuticals
  • Nifty 500

Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitionsand various organic…

178Announcements
08-09-2026Last filed
27Last 90 days

What Piramal files

  • Others47
  • Investor Meet43
  • Important30
  • Updates25
  • Board Meeting11
  • PPTs8
08-09-2026 · 03:37 pm

Piramal Pharma Limited is participating in physical group and one-on-one institutional investor meetings in the United Kingdom, arranged by Avendus Spark Institutional Equities. These discussions provide institutional investors an opportunity to engage directly with the company regarding its ongoing business operations.

Read the full announcement→
PDF
03-09-2026 · 02:35 pm

Piramal Pharma received an improved ESG rating of 65 for FY26 from NSE Sustainability, up from 64. This highlights the company's ongoing commitment to sustainability and responsible operations.

Read the full announcement→
PDF
27-08-2026 · 06:48 pm

CA Alchemy Investments, a shareholder in Piramal Pharma, has re-pledged 9.84 Cr (98,400,000) shares, representing 7.39% of the company. Deutsche Bank AG, acting as a security agent, now holds a pledge over a total of 23.87 Cr (238,663,700) Piramal Pharma shares, accounting for 17.93% of the equity. This re-pledge follows...

Read the full announcement→
PDF
24-08-2026 · 05:08 pm

Piramal Pharma reported ₹8,869 Cr revenue, ₹1,135 Cr EBITDA, and a ₹325.94 Cr net loss amid market headwinds. The company invested ₹890 Cr and US$90M in advanced therapies, boosting growth prospects. Operational excellence drove 22.6% emissions cut & 41% renewable energy, with advancing digital transformation.

Read the full announcement→
PDF
18-08-2026 · 11:38 am

Piramal Pharma (PPL) has acquired an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores, increasing its total ownership to 74.00%. Yapan, now a PPL subsidiary, specializes as a Contract Development and Manufacturing Organization (CDMO) for vaccines and biologics. This strategic acquisition integrates Yapan's advanced large molecule...

Read the full announcement→
PDF